| Recruitment status | Completed |
| Unique ID issued by UMIN | UMIN000034606 |
| Receipt No. | R000039450 |
| Scientific Title | The effects of novel chocolate on postprandial blood glucose level in healthy adults |
| Date of disclosure of the study information | 2018/12/24 |
| Last modified on | 2019/08/14 (Ver. 3) |
| Basic information | ||
| Public title | The effects of novel chocolate on postprandial blood glucose level in healthy adults | |
| Acronym | The effects of dietary novel chocolate on postprandial blood glucose | |
| Scientific Title | The effects of novel chocolate on postprandial blood glucose level in healthy adults | |
| Scientific Title:Acronym | The effects of dietary novel chocolate on postprandial blood glucose | |
| Region |
|
|
| Condition | ||
| Condition | Healthy adults | |
| Classification by specialty |
|
|
| Classification by malignancy | Others | |
| Genomic information | NO | |
| Objectives | |
| Narrative objectives1 | We randomly allocated twelve subjects to administer any of the novel chocolate, the control chocolate, and the sugar to investigate the postprandial blood glucose level, followed by a washout period. These subjects were then crossed over and received the alternative chocolate. |
| Basic objectives2 | Safety,Efficacy |
| Basic objectives -Others | |
| Trial characteristics_1 | |
| Trial characteristics_2 | |
| Developmental phase | |
| Assessment | |
| Primary outcomes | Blood glucose level, the blood glucose areas under the curve (AUC), the maximum blood glucose level(Cmax) , and time to reach Cmax(Tmax) |
| Key secondary outcomes | |
| Base | |
| Study type | Interventional |
| Study design | |
| Basic design | Cross-over |
| Randomization | Randomized |
| Randomization unit | Individual |
| Blinding | Open -no one is blinded |
| Control | Placebo |
| Stratification | NO |
| Dynamic allocation | NO |
| Institution consideration | |
| Blocking | YES |
| Concealment | Pseudo-randomization |
| Intervention | ||
| No. of arms | 3 | |
| Purpose of intervention | Treatment | |
| Type of intervention |
|
|
| Interventions/Control_1 | Single dose administration of 65 g of the novel chocolate in intervention period | |
| Interventions/Control_2 | Single dose administration of 65 g of the control chocolate in control period | |
| Interventions/Control_3 | Single dose administration of 19.2 g of sugars in sugars period | |
| Interventions/Control_4 | ||
| Interventions/Control_5 | ||
| Interventions/Control_6 | ||
| Interventions/Control_7 | ||
| Interventions/Control_8 | ||
| Interventions/Control_9 | ||
| Interventions/Control_10 | ||
| Eligibility | ||||
| Age-lower limit |
|
|||
| Age-upper limit |
|
|||
| Gender | Male and Female | |||
| Key inclusion criteria | 1) All subjects voluntarily signed the informed consent after detailed description and understanding of this study
2) Those who belong to a particular university. 3) Subjects with fasting blood glucose level within normal range between 70 mg/dL and 110 mg/dL using the first blood test 4) Subjects with systolic blood pressure under 140 mmHg and diastolic blood pressure under 90 mm Hg 5) Subjects with BMI above 18.5 kg/ m2-under 30 kg/ m2 6) Females who have a regular menstrual cycle, which is 25 to 38 days, and at the first test, who are from 14 days after the start of their menstruation to the next menstruation. 7) Non-smokers |
|||
| Key exclusion criteria | 1) Those who administer ''Food for Specified Health Use'', ''Foods with Function Claims'' or medicine to have effects on blood glucose metabolism.
2) Patients with diseases undergoing treatments or with medical history of severe diseases. 3) Patients who have severe diseases: diabetes, liver disease, kidney disease, heart disease (or persons who have history of these diseases). 4) Those who may suffer from allergy by administering milk, soybean, or cacao mass (chocolate). 5) Subjects who are in pregnancy, lactation. 6) Those who were included other clinical trials within one month before giving written informed consent, or during this study. 7) Any other medical and/or health reasons unfavorable to participation in this study, as judged by the principal investigator or examination doctor. |
|||
| Target sample size | 12 | |||
| Research contact person | |||||||
| Name of lead principal investigator |
|
||||||
| Organization | Suzuka University of Medical Science | ||||||
| Division name | Faculty of Health Science | ||||||
| Zip code | |||||||
| Address | 1001-1, Kishioka, Suzuka-city, Mie, 510-0293 | ||||||
| TEL | 059-383-8991 | ||||||
| miura@suzuka-u.ac.jp | |||||||
| Public contact | |||||||
| Name of contact person |
|
||||||
| Organization | Meiji Co., Ltd. | ||||||
| Division name | Group2, Food Science & Technology Research Laboratories, R&D Division | ||||||
| Zip code | |||||||
| Address | 1-29-1 Nanakuni, Hachiouji, Tokyo 192-0919 | ||||||
| TEL | 042-632-5850 | ||||||
| Homepage URL | |||||||
| midori.natsume@meiji.com | |||||||
| Sponsor | |
| Institute | Suzuka University of Medical Science |
| Institute | |
| Department | |
| Funding Source | |
| Organization | Meiji Co., Ltd. |
| Organization | |
| Division | |
| Category of Funding Organization | Profit organization |
| Nationality of Funding Organization | Japan |
| Other related organizations | |
| Co-sponsor | |
| Name of secondary funder(s) | |
| IRB Contact (For public release) | |
| Organization | |
| Address | |
| Tel | |
| Secondary IDs | |
| Secondary IDs | NO |
| Study ID_1 | |
| Org. issuing International ID_1 | |
| Study ID_2 | |
| Org. issuing International ID_2 | |
| IND to MHLW | |
| Institutions | |
| Institutions | 鈴鹿医療科学大学(三重県) |
| Other administrative information | |||||||
| Date of disclosure of the study information |
|
||||||
| Related information | |
| URL releasing protocol | |
| Publication of results | Published |
| Result | |||||||
| URL related to results and publications | |||||||
| Number of participants that the trial has enrolled | 11 | ||||||
| Results | 1) Analysis of all subjects revealed no significant difference between the control and test diets. 2) The test diet showed significant decrease in incremental area under the curve when compared with sucrose only while control diet did not change. 3) Compared to sucrose only, the chocolate with or without fructooligosaccharides significantly decreased blood glucose and Cmax. |
||||||
| Results date posted |
|
||||||
| Results Delayed | |||||||
| Results Delay Reason | |||||||
| Date of the first journal publication of results |
|
||||||
| Baseline Characteristics | |||||||
| Participant flow | |||||||
| Adverse events | None |
||||||
| Outcome measures | |||||||
| Plan to share IPD | |||||||
| IPD sharing Plan description | |||||||
| Progress | |||||||
| Recruitment status | Completed | ||||||
| Date of protocol fixation |
|
||||||
| Date of IRB | |||||||
| Anticipated trial start date |
|
||||||
| Last follow-up date | |||||||
| Date of closure to data entry | |||||||
| Date trial data considered complete | |||||||
| Date analysis concluded | |||||||
| Other | |
| Other related information | |
| Management information | |||||||
| Registered date |
|
||||||
| Last modified on |
|
||||||
| Link to view the page | |
| URL(English) | https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000039450 |